Pemefolacianine for IMI of Lung Cancer

The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of Pemefolacianine for Injection, a novel fluorescence imaging agent developed by Nanjing Nuoyuan Medical Devices Co., Ltd (Nuoyuan Medical), administered by slow intravenous (IV) in patients undergoing surgical thoracoscopy and/or RATS (Robot-Assisted Thoracoscopic Surgery) resection of lung cancer. Safety is the primary objective of this study, followed by evaluation of the fluorescence signal as it relates to dose level and dosing time interval which will not be used for decision-making in t

Trial Details

NCT ID
NCT07772895
Phase
PHASE1
Sponsor
Sunil Singhal
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pemefolacianine Cohort 1 in Part A
  • Pemefolacianin Cohort 2 in Part B
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Male or Female subjects greater than 18 years of age inclusive, at the time of signing the informed consent.
  • Have a primary diagnosis, or a high clinical suspicion, for cancer in the lung based on CT, biopsy, or other imaging.
  • Are scheduled to undergo surgical thoracoscopy or open surgery (thoracotomy) and resection of the lung.
  • If of childbearing potential, the patient must have a negative serum pregnancy test at screening, on Day 1 prior to Pemefolacianine for Injection a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →